Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuke Zhixue Xiaotong Granules
- Development stage
- Unknown
- Lead developer
- Fangsheng Pharmaceutical
- Administration
- Oral
01
Overview
Fuke Zhixue Xiaotong Granules is an investigational Traditional Chinese Medicine (TCM) developed by Hunan Fangsheng Pharmaceutical for the treatment of gynecological disorders characterized by bleeding and pain. As a herbal formulation, it is designed to address symptoms such as abnormal uterine bleeding and associated pelvic pain through the principles of TCM, which typically involve regulating blood flow and resolving stasis. The drug is currently in late-stage clinical development (Phase 3) in China, following the regulatory pathway for innovative TCM products.
- Other names
- 妇科止血消痛颗粒Fuke Zhixue Xiaotong Keli
Beyond the preview
Go deeper on Fuke Zhixue Xiaotong Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fuke Zhixue Xiaotong Granules.